Skip to main content
Clinical Trials/JPRN-UMIN000028989
JPRN-UMIN000028989
Completed
Phase 4

Prospective observational study on the key drug selection in advanced/recurrent EGFR mutation-positive non-small-cell lung cancer - Prospective observational study on the key drug selection in advanced/recurrent EGFR mutation-positive non-small-cell lung cancer

Osaka International Cancer Institute0 sites524 target enrollmentSeptember 10, 2017

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Osaka International Cancer Institute
Enrollment
524
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 10, 2017
End Date
May 31, 2020
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patients judged by the investigator to be unsuitable for the study

Outcomes

Primary Outcomes

Not specified

Similar Trials